(+)-VINCRISTINE
Adenocarcinoma of the Prostate
Fred Hutchinson Cancer CenterSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 89/ 100
Competitive context
16 Active assets in the Adenocarcinoma of the Prostate cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel Instituto do Cancer do Estado de São Paulo | Phase 3 | BBB |
PREDNISONE TABLETS Mayo Clinic | Phase 3 | BB |
Cyclophosphamide Beijing Biotech | Phase 2 | BB |
NILUTAMIDE SWOG Cancer Research Network | Phase 3 | BB |
Casodex OHSU Knight Cancer Institute | Phase 3 | BB |
View all 50 →
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →